[go: up one dir, main page]

NO20062146L - Nukleosidforbindelser for behandling av virusinfeksjoner - Google Patents

Nukleosidforbindelser for behandling av virusinfeksjoner

Info

Publication number
NO20062146L
NO20062146L NO20062146A NO20062146A NO20062146L NO 20062146 L NO20062146 L NO 20062146L NO 20062146 A NO20062146 A NO 20062146A NO 20062146 A NO20062146 A NO 20062146A NO 20062146 L NO20062146 L NO 20062146L
Authority
NO
Norway
Prior art keywords
viral infections
treatment
nucleoside compounds
compounds
virus
Prior art date
Application number
NO20062146A
Other languages
English (en)
Inventor
Natalia B Dyatkina
Christopher Don Roberts
Jesse D Keicher
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34557362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062146(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US10/861,090 external-priority patent/US7202223B2/en
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Publication of NO20062146L publication Critical patent/NO20062146L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Utgreid er forbindelser, sammensetninger og fremgangsmåter for å behandle virale infeksjoner forårsaket av en flaviviridae-familievirus slik som hepatitt-C-virus.
NO20062146A 2003-10-27 2006-05-12 Nukleosidforbindelser for behandling av virusinfeksjoner NO20062146L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51515303P 2003-10-27 2003-10-27
US10/861,090 US7202223B2 (en) 2003-10-27 2004-06-04 Nucleoside compounds for treating viral infections
US60281504P 2004-08-18 2004-08-18
PCT/US2004/034955 WO2005042556A1 (en) 2003-10-27 2004-10-20 Nucleoside compounds for treating viral infections

Publications (1)

Publication Number Publication Date
NO20062146L true NO20062146L (no) 2006-07-21

Family

ID=34557362

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062146A NO20062146L (no) 2003-10-27 2006-05-12 Nukleosidforbindelser for behandling av virusinfeksjoner

Country Status (15)

Country Link
US (1) US7157434B2 (no)
EP (1) EP1680436A1 (no)
JP (1) JP2007509939A (no)
KR (1) KR20060096487A (no)
AR (1) AR046202A1 (no)
AU (1) AU2004285923A1 (no)
BR (1) BRPI0415883A (no)
CA (1) CA2542776A1 (no)
IL (1) IL174685A0 (no)
MX (1) MXPA06004680A (no)
NO (1) NO20062146L (no)
SV (1) SV2005001920A (no)
TW (3) TW200524606A (no)
UY (1) UY28581A1 (no)
WO (1) WO2005042556A1 (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
YU92202A (sh) 2000-05-26 2006-01-16 Idenix (Cayman) Limited Metode i smeše za lečenje flavi virusa i pesti virusa
AU2003248748A1 (en) * 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
PT1576138T (pt) * 2002-11-15 2017-05-03 Idenix Pharmaceuticals Llc 2'-metil-nucleósidos em combinação com interferão e mutação de flaviviridae
RU2005121904A (ru) 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов
JP2007512359A (ja) 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
AU2006249350B2 (en) 2003-11-19 2012-02-16 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
US20050182252A1 (en) * 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
WO2006121468A1 (en) 2004-11-22 2006-11-16 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
CN101142226A (zh) 2005-02-28 2008-03-12 健亚生物科技公司 用于治疗病毒感染的三环核苷化合物
WO2007084157A2 (en) * 2005-03-23 2007-07-26 Genelabs Technologies, Inc. Nucleoside prodrugs for treating viral infections
WO2006102594A1 (en) * 2005-03-23 2006-09-28 Genelabs Technologies, Inc. Nucleoside prodrugs for treating viral infections
TW200720285A (en) * 2005-04-25 2007-06-01 Genelabs Tech Inc Nucleoside compounds for treating viral infections
DK1907000T4 (da) 2005-06-08 2020-03-30 The President And Fellows Of Harvard College Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007075876A2 (en) * 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
EP2124555B1 (en) * 2007-01-05 2015-07-08 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
TW200838550A (en) * 2007-02-09 2008-10-01 Novartis Ag Organic compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
WO2010015637A1 (en) * 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
JP5520961B2 (ja) 2008-11-28 2014-06-11 エモリー ユニバーシティ 感染症および腫瘍を処置するための方法
US8716263B2 (en) * 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
JP5721275B2 (ja) * 2009-04-22 2015-05-20 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ． 治療的使用のための新規７−デアザプリンヌクレオシド
NZ603606A (en) 2010-05-28 2015-06-26 Sarepta Therapeutics Inc Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
US8871737B2 (en) 2010-09-22 2014-10-28 Alios Biopharma, Inc. Substituted nucleotide analogs
AU2012340390B2 (en) 2011-11-18 2016-11-24 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
RU2015148006A (ru) 2013-04-12 2017-05-18 Ачиллион Фармасютикалз, Инк. Дейтерированные нуклеозидные пролекарства, применимые для лечения hcv
TWI574691B (zh) 2013-07-18 2017-03-21 Taiho Pharmaceutical Co Ltd Anti - tumor agents for intermittent administration of FGFR inhibitors
CA2921208C (en) 2013-08-12 2018-02-20 Taiho Pharmaceutical Co., Ltd. Fused pyrimidine compound or salt thereof
WO2015123352A1 (en) 2014-02-13 2015-08-20 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2016003812A1 (en) 2014-07-02 2016-01-07 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
RU2020126177A (ru) 2018-01-09 2022-02-10 Лиганд Фармасьютикалз, Инк. Ацетальные соединения и их терапевтическое применение
KR20200138283A (ko) 2018-03-22 2020-12-09 바이킹 테라퓨틱스 인코포레이티드 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140851A (en) * 1977-11-21 1979-02-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis and antitumor activity of 2,4,5-trisubstituted-pyrrolo2,3-d]-pyrimidine nucleosides
JPS61229897A (ja) 1985-04-05 1986-10-14 Nippon Zoki Pharmaceut Co Ltd 新規ヌクレオシド化合物
US6211158B1 (en) * 1987-04-10 2001-04-03 Roche Diagnostics Gmbh Desazapurine-nucleotide derivatives, processes for the preparation thereof, pharmaceutical compositions containing them and the use thereof for nucleic acid sequencing and as antiviral agents
US4892865A (en) * 1987-12-01 1990-01-09 The Regents Of The University Of Michigan Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US4968686A (en) * 1988-04-08 1990-11-06 The Regents Of The University Of Michigan Acyclic pyrrolo [2,3-d]pyrimidine analogs as antiviral agents
US4927830A (en) * 1988-04-08 1990-05-22 The Regents Of The University Of Michigan Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents
US5824796A (en) * 1988-09-28 1998-10-20 Epoch Pharmaceuticals, Inc. Cross-linking oligonucleotides
US5763597A (en) * 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. Orally active adenosine kinase inhibitors
WO1991010671A1 (en) 1990-01-11 1991-07-25 Isis Pharmaceuticals, Inc. Compositions and methods for detecting and modulating rna activity and gene expression
US5681941A (en) * 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
CA2154681A1 (en) 1993-02-03 1994-08-18 Mark David Erion Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
EP0695306A1 (en) 1993-04-19 1996-02-07 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
CA2171868A1 (en) 1993-09-17 1995-03-23 Petr Alexander Method for dosing therapeutic compounds
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US6150510A (en) * 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
DE4438918A1 (de) * 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US6004939A (en) * 1995-07-06 1999-12-21 Ctrc Research Foundation Board Of Regents Methods for modulation and inhibition of telomerase
WO1997002279A1 (en) * 1995-07-06 1997-01-23 Ctrc Research Foundation Methods and compositions for modulation and inhibition of telomerase
FR2750435B1 (fr) 1996-06-27 1998-08-28 Appligene Oncor Procede de formation de complexes d'hybridation dont la stabilite depend peu de la composition en base des deux molecules d'acides nucleiques hybridees
US6831069B2 (en) * 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
EP1138689A1 (en) 2000-03-28 2001-10-04 Roche Diagnostics GmbH N8- and C8-linked purine bases as universal nucleosides used for oligonucleotide hybridization
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
CN1267446C (zh) * 2001-01-22 2006-08-02 默克公司 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物
WO2003051899A1 (en) 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
WO2003055896A2 (en) 2001-12-21 2003-07-10 Micrologix Biotech Inc. Anti-viral 7-deaza l-nucleosides
WO2003062256A1 (en) * 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
WO2003068244A1 (en) 2002-02-13 2003-08-21 Merck & Co., Inc. Methods of inhibiting orthopoxvirus replication with nucleoside compounds
US20040014108A1 (en) * 2002-05-24 2004-01-22 Eldrup Anne B. Oligonucleotides having modified nucleoside units
US20040014957A1 (en) * 2002-05-24 2004-01-22 Anne Eldrup Oligonucleotides having modified nucleoside units
WO2004007512A2 (en) 2002-07-16 2004-01-22 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2003254657A1 (en) 2002-07-25 2004-02-16 Micrologix Biotech Inc. Anti-viral 7-deaza d-nucleosides and uses thereof
NZ538457A (en) 2002-09-30 2008-04-30 Genelabs Tech Inc Nucleoside derivatives for treating hepatitis C virus infection
US7094768B2 (en) * 2002-09-30 2006-08-22 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis C virus infection
WO2004043978A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations

Also Published As

Publication number Publication date
SV2005001920A (es) 2005-08-18
TW200524587A (en) 2005-08-01
BRPI0415883A (pt) 2007-01-09
EP1680436A1 (en) 2006-07-19
KR20060096487A (ko) 2006-09-11
US7157434B2 (en) 2007-01-02
AU2004285923A1 (en) 2005-05-12
JP2007509939A (ja) 2007-04-19
IL174685A0 (en) 2006-08-20
CA2542776A1 (en) 2005-05-12
TW200524606A (en) 2005-08-01
TW200528466A (en) 2005-09-01
WO2005042556A1 (en) 2005-05-12
US20050107312A1 (en) 2005-05-19
MXPA06004680A (es) 2007-04-17
AR046202A1 (es) 2005-11-30
UY28581A1 (es) 2005-05-31

Similar Documents

Publication Publication Date Title
NO20062146L (no) Nukleosidforbindelser for behandling av virusinfeksjoner
TW200602064A (en) Nucleoside derivatives for treating hepatitis C virus infection
NO20045247L (no) Nukleosidderivater for behandling av hepatitt C-virusinfeksjon
EA200500584A1 (ru) Нуклеозидные производные для лечения инфекционных заболеваний, вызванных вирусом гепатита c
NO20070751L (no) Inhibitorer av HCV-replifikasjon
TW200720285A (en) Nucleoside compounds for treating viral infections
NO20092053L (no) HCV NS3-proteaseinhibitorer
NO20074613L (no) Tricykliske nukleosidforbindelser for behandling av virale infeksjoner
EA201000201A1 (ru) Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
TW200517381A (en) Bicyclic heteroaryl derivatives
NO20073849L (no) Indolderivater for behandling av virale infeksjoner
NO20080879L (no) HCV-NS3-proteaseinhibitorer
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
DK1569929T3 (da) Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
EA200501689A1 (ru) Соединения в качестве ингибиторов вируса гепатита c
EA200900298A1 (ru) Ингибиторы вируса гепатита с
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EA200901241A1 (ru) Соединения для лечения гепатита с
NO20090453L (no) Hepatitt C Virusinhibitorer
NO20073105L (no) Pyridazinonforbindelser
NO20070194L (no) Fremgangsmater for behandling av hepatitt C
TW200719898A (en) 6-membered aryl and heteroaryl derivatives for treating viruses
EA201000277A1 (ru) Соединения для лечения гепатита с
UY27798A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatits c y composiciones y tratamientos que los usan.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application